Autopsy report · NCT02069834

Dolutegravir + Rilpivirine Switch Study (DORISS)

“One of the both Funder partners decided to stop the study before the initiation : thus no product provided and no funding to realize the study”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2, Phase 3

Sponsor

Nantes University Hospital

Sponsor type

University, hospital or other

Conditions

HIV Infection; HAART-treated; Virologically Controlled

Interventions

Arm 1 (intervention); Arm 2 (control)

Participants

0

Sites

25

Countries

France

Trials that died the same way

• Angiotensin 2 for Hepatorenal Syndrome
  “Funding issues; the study was never started” (73% match in meaning)
• AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial
  “With available funding it was necessary for Sponsor to prioritize other studies. No study participants were consented or enrolled and no study sites were activated.” (73% match in meaning)
• Pasireotide in Hyperinsulinemic Hypoglycemia
  “Funding was withdrawn by Sponsor prior to start of study” (72% match in meaning)
• Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health
  “Funding for this study was discontinued by the sponsor after the first year.” (71% match in meaning)
• Parkinson's Disease G2019S LRRK2 Genetic Testing Program
  “Sponsor stopped the study” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.